Ascendis Pharma A/S (NASDAQ:ASND) Holdings Boosted by Vestal Point Capital LP

Vestal Point Capital LP grew its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 108.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 520,000 shares of the biotechnology company’s stock after purchasing an additional 270,000 shares during the quarter. Ascendis Pharma A/S makes up 4.2% of Vestal Point Capital LP’s holdings, making the stock its 4th biggest position. Vestal Point Capital LP owned about 0.86% of Ascendis Pharma A/S worth $71,588,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S in the 4th quarter valued at $28,000. Jones Financial Companies Lllp grew its holdings in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. raised its position in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 328 shares during the last quarter. Quarry LP purchased a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $96,000. Finally, Tower Research Capital LLC TRC boosted its position in Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 664 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $157.60 on Monday. The company’s 50-day simple moving average is $157.15 and its 200-day simple moving average is $142.64. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00. The stock has a market capitalization of $9.61 billion, a PE ratio of -22.20 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ASND shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Evercore ISI increased their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Morgan Stanley upgraded Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $180.00 to $250.00 in a research report on Monday, May 5th. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Royal Bank of Canada lifted their price target on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $216.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.